| First Author | Hu JJ | Year | 2020 |
| Journal | Nat Immunol | Volume | 21 |
| Issue | 7 | Pages | 736-745 |
| PubMed ID | 32367036 | Mgi Jnum | J:306397 |
| Mgi Id | MGI:6706647 | Doi | 10.1038/s41590-020-0669-6 |
| Citation | Hu JJ, et al. (2020) FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol 21(7):736-745 |
| abstractText | Cytosolic sensing of pathogens and damage by myeloid and barrier epithelial cells assembles large complexes called inflammasomes, which activate inflammatory caspases to process cytokines (IL-1beta) and gasdermin D (GSDMD). Cleaved GSDMD forms membrane pores, leading to cytokine release and inflammatory cell death (pyroptosis). Inhibiting GSDMD is an attractive strategy to curb inflammation. Here we identify disulfiram, a drug for treating alcohol addiction, as an inhibitor of pore formation by GSDMD but not other members of the GSDM family. Disulfiram blocks pyroptosis and cytokine release in cells and lipopolysaccharide-induced septic death in mice. At nanomolar concentration, disulfiram covalently modifies human/mouse Cys191/Cys192 in GSDMD to block pore formation. Disulfiram still allows IL-1beta and GSDMD processing, but abrogates pore formation, thereby preventing IL-1beta release and pyroptosis. The role of disulfiram in inhibiting GSDMD provides new therapeutic indications for repurposing this safe drug to counteract inflammation, which contributes to many human diseases. |
